月経困難症治療市場：世界の産業分析、規模、シェア、成長、動向、予測、2024年～2031年

Persistence Market Research社はこのほど、世界の月経困難症治療市場に関する包括的なレポートを発表しました。当レポートでは、市場促進要因・動向・機会・課題を含む重要な市場力学を徹底的に評価し、市場構造に関する詳細な洞察を提供しています。

主要な洞察

• 月経困難症治療市場規模（2024年）：61億米ドル
• 予測市場規模（2031年）：109億米ドル
• 世界市場成長率（CAGR 2024年から2031年まで）：8.6%

月経困難症治療市場- レポート範囲：

痛みを伴う月経痛を特徴とする月経困難症は、世界の女性人口のかなりの部分に影響を与えています。月経困難症治療市場は、医薬品、市販鎮痛剤、ホルモン治療、代替医療など、幅広い治療オプションに対応しています。市場成長の原動力は、月経困難症の有病率の増加、治療オプションに対する意識の高まり、症状管理と患者のQOL向上を目指した医学研究の進歩です。

市場促進要因：

世界の月経困難症治療市場は、効果的な治療オプションの利用可能性に関する意識の高まりや、生殖年齢の女性における月経困難症の有病率の増加など、いくつかの重要な要因によって推進されています。薬剤製剤の進歩や、非ホルモン薬や標的療法などの新規治療法の開拓が、市場の拡大に寄与しています。さらに、先進国市場と新興国市場の両方で、ヘルスケア支出の増加と多様な治療オプションが利用可能であることが、市場の成長をさらに後押ししています。

市場抑制要因：

有望な成長見通しにもかかわらず、月経困難症治療市場は、先進的な治療オプションの高額な費用や、特定の地域におけるヘルスケアへのアクセスの制限に関連する課題に直面しています。また、治療効果のばらつきや患者の治療遵守の問題も課題となっています。さらに、規制上のハードルや、新しい治療法を検証するための継続的な臨床試験の必要性は、市場のダイナミクスに影響を与え、革新的な治療ソリューションの導入を遅らせる可能性があります。

市場機会：

月経困難症治療市場は、技術革新、研究開発投資の増加、個別化医療への注目の高まりにより、大きな成長機会をもたらしています。症状追跡用のモバイルヘルスアプリや遠隔医療プラットフォームなどのデジタルヘルス技術の統合は、患者の治療へのアクセスを強化し、治療のアドヒアランスを向上させる。さらに、月経困難症とその治療選択肢に関する啓発キャンペーンや教育プログラムの拡大は、市場の成長を促進し、早期診断と効果的な管理を促すことができます。

本レポートで扱う主な質問

• 月経困難症治療市場の世界の成長を促進する主な要因は何か？
• 月経困難症の治療に最も効果的な治療オプションやアプローチは何か？
• 技術進歩や研究革新は月経困難症治療市場の競合情勢にどのような影響を与えているか？
• 月経困難症治療市場に貢献している主要企業はどこか、また市場の関連性を維持するためにどのような戦略を採用しているか？
• 世界の月経困難症治療市場の新たな動向と将来展望は？

目次

第1章 エグゼクティブサマリー

第2章 市場概要

• 市場の範囲と定義
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
  • 課題
  • 主な動向
• 疾患ライフサイクル分析
• 月経困難症治療市場：バリューチェーン
  • 原材料サプライヤー一覧
  • メーカー一覧
  • 販売代理店一覧
  • アプリケーション一覧
  • 収益性分析
• ポーターファイブフォースの分析
• 地政学的緊張：市場への影響
• マクロ経済要因
  • 世界のセクター別展望
  • 世界のGDP成長見通し
  • 世界の親市場概要
• 予測要因- 関連性と影響
• 規制とテクノロジーの情勢

第3章 世界の月経困難症治療市場の展望：過去および予測

• 主なハイライト
  • 市場規模予測
  • 市場規模と前年比成長率
  • 絶対的な$機会
• 市場規模の分析と予測
  • 過去の市場規模分析、2019-2023
  • 現在の市場規模予測、2024-2031
• 世界の月経困難症治療市場の展望：疾患別
  • イントロダクション/主な調査結果
  • 過去の市場規模（10億米ドル）と数量分析：疾患別、2019年～2023年
  • 現在および将来の市場規模（10億米ドル）と数量予測、疾患別、2024～2031年
    • 原発性月経困難症
    • 二次性月経困難症
    • 子宮内膜症
    • 子宮腺筋症
    • 子宮筋腫
    • 子宮内膜ポリープ
    • 頸管狭窄症
    • 生殖管閉塞性奇形
• 市場の魅力分析：疾患別
• 世界の月経困難症治療市場の展望：治療クラス別
  • イントロダクション/主な調査結果
  • 過去の市場規模（10億米ドル）と数量分析：治療クラス別、2019年～2023年
  • 現在および将来の市場規模（10億米ドル）と数量予測、治療クラス別、2024～2031年
    • 非ホルモン治療
    • 非ステロイド性抗炎症薬（NSAID）
    • 非選択的NSAID
    • COX-2阻害剤
    • 経皮吸収型グリセリルトリニトレート
    • 市販薬（OTC）
    • ホルモン薬による治療
    • 複合経口避妊薬
    • プロゲスチン療法
    • レボノルゲストレル子宮内システム（LN-IUS）
    • 外科的治療の選択肢
    • 腹腔鏡検査
    • 子宮摘出
    • 仙骨前神経切除術
    • 腹腔鏡下子宮仙骨神経アブレーション（LUNA）
    • 子宮内避妊器具（IUD）
• 市場の魅力分析：治療クラス別

第4章 世界の月経困難症治療市場の展望：地域別

• 主なハイライト
• 過去の市場規模（10億米ドル）と数量分析：地域別、2019年～2023年
• 現在および将来の市場規模（10億米ドル）と数量予測、地域別、2024～2031年
  • 北米
  • 欧州
  • 東アジア
  • 南アジアとオセアニア
  • ラテンアメリカ
  • 中東・アフリカ
• 市場の魅力分析：地域別

第5章 北米の月経困難症治療市場の展望：過去（2019年～2023年）および予測（2024年～2031年）

第6章 欧州の月経困難症治療市場の展望：過去（2019年～2023年）および予測（2024年～2031年）

第7章 東アジアの月経困難症治療市場の展望：過去（2019年～2023年）および予測（2024年～2031年）

第8章 南アジアおよびオセアニアの月経困難症治療市場の展望：過去（2019年～2023年）および予測（2024年～2031年）

第9章 ラテンアメリカの月経困難症治療市場の展望：過去（2019年～2023年）および予測（2024年～2031年）

第10章 中東およびアフリカの月経困難症治療市場の展望：過去（2019年～2023年）および予測（2024年～2031年）

第11章 競合情勢

• 市場シェア分析、2024年
• 市場構造
  • 市場別の競合激化マップ
  • 競合ダッシュボード
  • 見かけの製品容量
• 企業プロファイル（詳細- 概要、財務、戦略、最近の動向）
  • Novartis Pharmaceuticals Corporation
  • Merck, Inc.
  • Bayer Schering Pharma AG
  • Vanita Therapeutics
  • Alvogen
  • Pfizer, Inc.
  • Nua
  • Cora
  • Roche Laboratories
  • Taj Pharmaceuticals, Ltd.
  • Sanofi
  • Terramedic, Inc.

第12章 付録

• 調査手法
• 調査の前提
• 頭字語と略語

Persistence Market Research has recently released a comprehensive report on the global Dysmenorrhea Treatment Market. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure.

Key Insights:

• Dysmenorrhea Treatment Market Size (2024E): USD 6.1 Billion
• Projected Market Value (2031F): USD 10.9 Billion
• Global Market Growth Rate (CAGR 2024 to 2031): 8.6%

Dysmenorrhea Treatment Market - Report Scope:

Dysmenorrhea, characterized by painful menstrual cramps, impacts a significant portion of the female population globally. The Dysmenorrhea Treatment Market caters to a wide range of therapeutic options, including pharmaceuticals, over-the-counter pain relievers, hormonal treatments, and alternative medicine. Market growth is driven by the increasing prevalence of dysmenorrhea, rising awareness of treatment options, and advancements in medical research aimed at improving symptom management and patient quality of life.

Market Growth Drivers:

The global Dysmenorrhea Treatment Market is propelled by several key factors, including growing awareness about the availability of effective treatment options and the increasing prevalence of dysmenorrhea among women of reproductive age. Advances in drug formulations and the development of novel therapies, such as non-hormonal medications and targeted therapies, contribute to the market's expansion. Additionally, rising healthcare expenditures and the availability of diverse treatment options in both developed and emerging markets further drive market growth.

Market Restraints:

Despite promising growth prospects, the Dysmenorrhea Treatment Market faces challenges related to the high cost of advanced treatment options and limited access to healthcare in certain regions. Variability in treatment efficacy and patient adherence issues also pose challenges. Furthermore, regulatory hurdles and the need for ongoing clinical trials to validate new therapies can impact market dynamics and slow the introduction of innovative treatment solutions.

Market Opportunities:

The Dysmenorrhea Treatment Market presents significant growth opportunities driven by technological innovations, increasing investment in research and development, and the growing focus on personalized medicine. The integration of digital health technologies, such as mobile health apps for symptom tracking and telemedicine platforms, enhances patient access to care and improves treatment adherence. Furthermore, expanding awareness campaigns and educational programs about dysmenorrhea and its treatment options can foster market growth and encourage early diagnosis and effective management.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the Dysmenorrhea Treatment Market globally?
• Which treatment options and approaches are most effective in managing dysmenorrhea?
• How are technological advancements and research innovations influencing the competitive landscape of the Dysmenorrhea Treatment Market?
• Who are the key players contributing to the Dysmenorrhea Treatment Market, and what strategies are they employing to maintain market relevance?
• What are the emerging trends and future prospects in the global Dysmenorrhea Treatment Market?

Competitive Intelligence and Business Strategy:

Leading players in the global Dysmenorrhea Treatment Market, including Pfizer Inc., Bayer AG, and Johnson & Johnson, focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop advanced treatment options, including novel pain management therapies and hormone-based treatments. Collaborations with healthcare providers, academic institutions, and regulatory agencies facilitate market access and promote technology adoption. Additionally, emphasis on clinical research, patient education, and targeted marketing strategies support market growth and enhance patient outcomes in the evolving Dysmenorrhea Treatment landscape.

Key Companies Profiled:

• Novartis Pharmaceuticals Corporation
• Merck, Inc.
• Bayer Schering Pharma AG
• Vanita Therapeutics
• Alvogen
• Pfizer, Inc.
• Nua
• Cora
• Roche Laboratories
• Taj Pharmaceuticals, Ltd.
• Sanofi
• Terramedic, Inc.

Dysmenorrhea Treatment Market Research Segmentation

By Diseases:

• Primary Dysmenorrhea
• Secondary Dysmenorrhea
• Endometriosis
• Adenomyosis
• Uterine Myomas
• Endometrial Polyps
• Cervical Stenosis
• Obstructive Malformations of Genital Tract

By Therapeutic Class:

• Non-Hormonal Medical Treatment
• Non-steroidal anti-inflammatory Drugs (NSAIDS)
• Non-Selective NSAIDs
• Cox-2 Inhibitors
• Transdermal Glyceryl Trinitrate
• Over-The-Counter (Otc) Medications
• Hormonal Medicine Treatment
• Combined Oral Contraceptive
• Progestin Regimens
• Levonorgestrel Intrauterine System (LN-IUS)
• Surgical Options
• Laparoscopy
• Hysterectomy
• Presacral Neurectomy
• Laparoscopic Uterosacral Nerve Ablation (LUNA)
• Intrauterine Device (IUD)

By Region:

• North America
• Europe
• East Asia
• South Asia & Oceania
• Latin America
• Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Dysmenorrhea Treatment Market Snapshot, 2024 - 2031
• 1.2. Market Opportunity Assessment, 2024 - 2031, US$ Mn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. Diseases Lifecycle Analysis
• 2.4. Dysmenorrhea Treatment Market: Value Chain
  • 2.4.1. List of Raw Material Supplier
  • 2.4.2. List of Manufacturers
  • 2.4.3. List of Distributors
  • 2.4.4. List of Applications
  • 2.4.5. Profitability Analysis
• 2.5. Porter Five Force's Analysis
• 2.6. Geopolitical Tensions: Market Impact
• 2.7. Macro-Economic Factors
  • 2.7.1. Global Sectorial Outlook
  • 2.7.2. Global GDP Growth Outlook
  • 2.7.3. Global Parent Market Overview
• 2.8. Forecast Factors - Relevance and Impact
• 2.9. Regulatory and Technology Landscape

3. Global Dysmenorrhea Treatment Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

• 3.1. Key Highlights
  • 3.1.1. Market Volume (Units) Projections
  • 3.1.2. Market Size and Y-o-Y Growth
  • 3.1.3. Absolute $ Opportunity
• 3.2. Market Size (US$ Bn) Analysis and Forecast
  • 3.2.1. Historical Market Size Analysis, 2019-2023
  • 3.2.2. Current Market Size Forecast, 2024 - 2031
• 3.3. Global Dysmenorrhea Treatment Market Outlook: Diseases
  • 3.3.1. Introduction / Key Findings
  • 3.3.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis By Disease, 2019-2023
  • 3.3.3. Current Market Size (US$ Bn) and Volume (Units) Forecast By Disease, 2024 - 2031
    • 3.3.3.1. Primary Dysmenorrhea
    • 3.3.3.2. Secondary Dysmenorrhea
    • 3.3.3.3. Endometriosis
    • 3.3.3.4. Adenomyosis
    • 3.3.3.5. Uterine Myomas
    • 3.3.3.6. Endometrial Polyps
    • 3.3.3.7. Cervical Stenosis
    • 3.3.3.8. Obstructive Malformations of Genital Tract
• 3.4. Market Attractiveness Analysis: Diseases
• 3.5. Global Dysmenorrhea Treatment Market Outlook: Therapeutic Class
  • 3.5.1. Introduction / Key Findings
  • 3.5.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis By Therapeutic Class, 2019-2023
  • 3.5.3. Current Market Size (US$ Bn) and Volume (Units) Forecast By Therapeutic Class, 2024 - 2031
    • 3.5.3.1. Non-Hormonal Medical Treatment
    • 3.5.3.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
    • 3.5.3.3. Non-Selective Nsaids
    • 3.5.3.4. Cox-2 Inhibitors
    • 3.5.3.5. Transdermal Glyceryl Trinitrate
    • 3.5.3.6. Over-The-Counter (Otc) Medications
    • 3.5.3.7. Hormonal Medicine Treatment
    • 3.5.3.8. Combined Oral Contraceptive
    • 3.5.3.9. Progestin Regimens
    • 3.5.3.10. Levonorgestrel Intrauterine System (LN-IUS)
    • 3.5.3.11. Surgical Options
    • 3.5.3.12. Laparoscopy
    • 3.5.3.13. Hysterectomy
    • 3.5.3.14. Presacral Neurectomy
    • 3.5.3.15. Laparoscopic Uterosacral Nerve Ablation (LUNA)
    • 3.5.3.16. Intrauterine Device (IUD)
• 3.6. Market Attractiveness Analysis: Therapeutic Class

4. Global Dysmenorrhea Treatment Market Outlook: Region

• 4.1. Key Highlights
• 4.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis By Region, 2019-2023
• 4.3. Current Market Size (US$ Bn) and Volume (Units) Forecast By Region, 2024 - 2031
  • 4.3.1. North America
  • 4.3.2. Europe
  • 4.3.3. East Asia
  • 4.3.4. South Asia and Oceania
  • 4.3.5. Latin America
  • 4.3.6. Middle East & Africa (MEA)
• 4.4. Market Attractiveness Analysis: Region

5. North America Dysmenorrhea Treatment Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

• 5.1. Key Highlights
• 5.2. Pricing Analysis
• 5.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis By Market, 2019-2023
  • 5.3.1. By Country
  • 5.3.2. By Disease
  • 5.3.3. By Therapeutic Class
• 5.4. Current Market Size (US$ Bn) and Volume (Units) Forecast By Country, 2024 - 2031
  • 5.4.1. U.S.
  • 5.4.2. Canada
• 5.5. Current Market Size (US$ Bn) and Volume (Units) Forecast By Disease, 2024 - 2031
  • 5.5.1. Primary Dysmenorrhea
  • 5.5.2. Secondary Dysmenorrhea
  • 5.5.3. Endometriosis
  • 5.5.4. Adenomyosis
  • 5.5.5. Uterine Myomas
  • 5.5.6. Endometrial Polyps
  • 5.5.7. Cervical Stenosis
  • 5.5.8. Obstructive Malformations of Genital Tract
• 5.6. Current Market Size (US$ Bn) and Volume (Units) Forecast By Therapeutic Class, 2024 - 2031
  • 5.6.1. Non-Hormonal Medical Treatment
  • 5.6.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
  • 5.6.3. Non-Selective Nsaids
  • 5.6.4. Cox-2 Inhibitors
  • 5.6.5. Transdermal Glyceryl Trinitrate
  • 5.6.6. Over-The-Counter (Otc) Medications
  • 5.6.7. Hormonal Medicine Treatment
  • 5.6.8. Combined Oral Contraceptive
  • 5.6.9. Progestin Regimens
  • 5.6.10. Levonorgestrel Intrauterine System (LN-IUS)
  • 5.6.11. Surgical Options
  • 5.6.12. Laparoscopy
  • 5.6.13. Hysterectomy
  • 5.6.14. Presacral Neurectomy
  • 5.6.15. Laparoscopic Uterosacral Nerve Ablation (LUNA)
  • 5.6.16. Intrauterine Device (IUD)
• 5.7. Market Attractiveness Analysis

6. Europe Dysmenorrhea Treatment Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

• 6.1. Key Highlights
• 6.2. Pricing Analysis
• 6.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis By Market, 2019-2023
  • 6.3.1. By Country
  • 6.3.2. By Disease
  • 6.3.3. By Therapeutic Class
• 6.4. Current Market Size (US$ Bn) and Volume (Units) Forecast By Country, 2024 - 2031
  • 6.4.1. Germany
  • 6.4.2. France
  • 6.4.3. U.K.
  • 6.4.4. Italy
  • 6.4.5. Spain
  • 6.4.6. Russia
  • 6.4.7. Turkiye
  • 6.4.8. Rest of Europe
• 6.5. Current Market Size (US$ Bn) and Volume (Units) Forecast By Disease, 2024 - 2031
  • 6.5.1. Primary Dysmenorrhea
  • 6.5.2. Secondary Dysmenorrhea
  • 6.5.3. Endometriosis
  • 6.5.4. Adenomyosis
  • 6.5.5. Uterine Myomas
  • 6.5.6. Endometrial Polyps
  • 6.5.7. Cervical Stenosis
  • 6.5.8. Obstructive Malformations of Genital Tract
• 6.6. Current Market Size (US$ Bn) and Volume (Units) Forecast By Therapeutic Class, 2024 - 2031
  • 6.6.1. Non-Hormonal Medical Treatment
  • 6.6.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
  • 6.6.3. Non-Selective Nsaids
  • 6.6.4. Cox-2 Inhibitors
  • 6.6.5. Transdermal Glyceryl Trinitrate
  • 6.6.6. Over-The-Counter (Otc) Medications
  • 6.6.7. Hormonal Medicine Treatment
  • 6.6.8. Combined Oral Contraceptive
  • 6.6.9. Progestin Regimens
  • 6.6.10. Levonorgestrel Intrauterine System (LN-IUS)
  • 6.6.11. Surgical Options
  • 6.6.12. Laparoscopy
  • 6.6.13. Hysterectomy
  • 6.6.14. Presacral Neurectomy
  • 6.6.15. Laparoscopic Uterosacral Nerve Ablation (LUNA)
  • 6.6.16. Intrauterine Device (IUD)
• 6.7. Market Attractiveness Analysis

7. East Asia Dysmenorrhea Treatment Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

• 7.1. Key Highlights
• 7.2. Pricing Analysis
• 7.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis By Market, 2019-2023
  • 7.3.1. By Country
  • 7.3.2. By Disease
  • 7.3.3. By Therapeutic Class
• 7.4. Current Market Size (US$ Bn) and Volume (Units) Forecast By Country, 2024 - 2031
  • 7.4.1. China
  • 7.4.2. Japan
  • 7.4.3. South Korea
• 7.5. Current Market Size (US$ Bn) and Volume (Units) Forecast By Disease, 2024 - 2031
  • 7.5.1. Primary Dysmenorrhea
  • 7.5.2. Secondary Dysmenorrhea
  • 7.5.3. Endometriosis
  • 7.5.4. Adenomyosis
  • 7.5.5. Uterine Myomas
  • 7.5.6. Endometrial Polyps
  • 7.5.7. Cervical Stenosis
  • 7.5.8. Obstructive Malformations of Genital Tract
• 7.6. Current Market Size (US$ Bn) and Volume (Units) Forecast By Therapeutic Class, 2024 - 2031
  • 7.6.1. Non-Hormonal Medical Treatment
  • 7.6.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
  • 7.6.3. Non-Selective Nsaids
  • 7.6.4. Cox-2 Inhibitors
  • 7.6.5. Transdermal Glyceryl Trinitrate
  • 7.6.6. Over-The-Counter (Otc) Medications
  • 7.6.7. Hormonal Medicine Treatment
  • 7.6.8. Combined Oral Contraceptive
  • 7.6.9. Progestin Regimens
  • 7.6.10. Levonorgestrel Intrauterine System (LN-IUS)
  • 7.6.11. Surgical Options
  • 7.6.12. Laparoscopy
  • 7.6.13. Hysterectomy
  • 7.6.14. Presacral Neurectomy
  • 7.6.15. Laparoscopic Uterosacral Nerve Ablation (LUNA)
  • 7.6.16. Intrauterine Device (IUD)
• 7.7. Market Attractiveness Analysis

8. South Asia & Oceania Dysmenorrhea Treatment Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

• 8.1. Key Highlights
• 8.2. Pricing Analysis
• 8.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis By Market, 2019-2023
  • 8.3.1. By Country
  • 8.3.2. By Disease
  • 8.3.3. By Therapeutic Class
• 8.4. Current Market Size (US$ Bn) and Volume (Units) Forecast By Country, 2024 - 2031
  • 8.4.1. India
  • 8.4.2. Southeast Asia
  • 8.4.3. ANZ
  • 8.4.4. Rest of South Asia & Oceania
• 8.5. Current Market Size (US$ Bn) and Volume (Units) Forecast By Disease, 2024 - 2031
  • 8.5.1. Primary Dysmenorrhea
  • 8.5.2. Secondary Dysmenorrhea
  • 8.5.3. Endometriosis
  • 8.5.4. Adenomyosis
  • 8.5.5. Uterine Myomas
  • 8.5.6. Endometrial Polyps
  • 8.5.7. Cervical Stenosis
  • 8.5.8. Obstructive Malformations of Genital Tract
• 8.6. Current Market Size (US$ Bn) and Volume (Units) Forecast By Therapeutic Class, 2024 - 2031
  • 8.6.1. Non-Hormonal Medical Treatment
  • 8.6.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
  • 8.6.3. Non-Selective Nsaids
  • 8.6.4. Cox-2 Inhibitors
  • 8.6.5. Transdermal Glyceryl Trinitrate
  • 8.6.6. Over-The-Counter (Otc) Medications
  • 8.6.7. Hormonal Medicine Treatment
  • 8.6.8. Combined Oral Contraceptive
  • 8.6.9. Progestin Regimens
  • 8.6.10. Levonorgestrel Intrauterine System (LN-IUS)
  • 8.6.11. Surgical Options
  • 8.6.12. Laparoscopy
  • 8.6.13. Hysterectomy
  • 8.6.14. Presacral Neurectomy
  • 8.6.15. Laparoscopic Uterosacral Nerve Ablation (LUNA)
  • 8.6.16. Intrauterine Device (IUD)
• 8.7. Market Attractiveness Analysis

9. Latin America Dysmenorrhea Treatment Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

• 9.1. Key Highlights
• 9.2. Pricing Analysis
• 9.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis By Market, 2019-2023
  • 9.3.1. By Country
  • 9.3.2. By Disease
  • 9.3.3. By Therapeutic Class
• 9.4. Current Market Size (US$ Bn) and Volume (Units) Forecast By Country, 2024 - 2031
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America
• 9.5. Current Market Size (US$ Bn) and Volume (Units) Forecast By Disease, 2024 - 2031
  • 9.5.1. Primary Dysmenorrhea
  • 9.5.2. Secondary Dysmenorrhea
  • 9.5.3. Endometriosis
  • 9.5.4. Adenomyosis
  • 9.5.5. Uterine Myomas
  • 9.5.6. Endometrial Polyps
  • 9.5.7. Cervical Stenosis
  • 9.5.8. Obstructive Malformations of Genital Tract
• 9.6. Current Market Size (US$ Bn) and Volume (Units) Forecast By Therapeutic Class, 2024 - 2031
  • 9.6.1. Non-Hormonal Medical Treatment
  • 9.6.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
  • 9.6.3. Non-Selective Nsaids
  • 9.6.4. Cox-2 Inhibitors
  • 9.6.5. Transdermal Glyceryl Trinitrate
  • 9.6.6. Over-The-Counter (Otc) Medications
  • 9.6.7. Hormonal Medicine Treatment
  • 9.6.8. Combined Oral Contraceptive
  • 9.6.9. Progestin Regimens
  • 9.6.10. Levonorgestrel Intrauterine System (LN-IUS)
  • 9.6.11. Surgical Options
  • 9.6.12. Laparoscopy
  • 9.6.13. Hysterectomy
  • 9.6.14. Presacral Neurectomy
  • 9.6.15. Laparoscopic Uterosacral Nerve Ablation (LUNA)
  • 9.6.16. Intrauterine Device (IUD)
• 9.7. Market Attractiveness Analysis

10. Middle East & Africa Dysmenorrhea Treatment Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

• 10.1. Key Highlights
• 10.2. Pricing Analysis
• 10.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis By Market, 2019-2023
  • 10.3.1. By Country
  • 10.3.2. By Disease
  • 10.3.3. By Therapeutic Class
• 10.4. Current Market Size (US$ Bn) and Volume (Units) Forecast By Country, 2024 - 2031
  • 10.4.1. GCC
  • 10.4.2. Egypt
  • 10.4.3. South Africa
  • 10.4.4. Northern Africa
  • 10.4.5. Rest of Middle East & Africa
• 10.5. Current Market Size (US$ Bn) and Volume (Units) Forecast By Disease, 2024 - 2031
  • 10.5.1. Primary Dysmenorrhea
  • 10.5.2. Secondary Dysmenorrhea
  • 10.5.3. Endometriosis
  • 10.5.4. Adenomyosis
  • 10.5.5. Uterine Myomas
  • 10.5.6. Endometrial Polyps
  • 10.5.7. Cervical Stenosis
  • 10.5.8. Obstructive Malformations of Genital Tract
• 10.6. Current Market Size (US$ Bn) and Volume (Units) Forecast By Therapeutic Class, 2024 - 2031
  • 10.6.1. Non-Hormonal Medical Treatment
  • 10.6.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
  • 10.6.3. Non-Selective Nsaids
  • 10.6.4. Cox-2 Inhibitors
  • 10.6.5. Transdermal Glyceryl Trinitrate
  • 10.6.6. Over-The-Counter (Otc) Medications
  • 10.6.7. Hormonal Medicine Treatment
  • 10.6.8. Combined Oral Contraceptive
  • 10.6.9. Progestin Regimens
  • 10.6.10. Levonorgestrel Intrauterine System (LN-IUS)
  • 10.6.11. Surgical Options
  • 10.6.12. Laparoscopy
  • 10.6.13. Hysterectomy
  • 10.6.14. Presacral Neurectomy
  • 10.6.15. Laparoscopic Uterosacral Nerve Ablation (LUNA)
  • 10.6.16. Intrauterine Device (IUD)
• 10.7. Market Attractiveness Analysis

11. Competition Landscape

• 11.1. Market Share Analysis, 2024
• 11.2. Market Structure
  • 11.2.1. Competition Intensity Mapping By Market
  • 11.2.2. Competition Dashboard
  • 11.2.3. Apparent Product Capacity
• 11.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 11.3.1. Novartis Pharmaceuticals Corporation
    • 11.3.1.1. Overview
    • 11.3.1.2. Segments and Product
    • 11.3.1.3. Key Financials
    • 11.3.1.4. Market Developments
    • 11.3.1.5. Market Strategy
  • 11.3.2. Merck, Inc.
    • 11.3.2.1. Overview
    • 11.3.2.2. Segments and Product
    • 11.3.2.3. Key Financials
    • 11.3.2.4. Market Developments
    • 11.3.2.5. Market Strategy
  • 11.3.3. Bayer Schering Pharma AG
    • 11.3.3.1. Overview
    • 11.3.3.2. Segments and Product
    • 11.3.3.3. Key Financials
    • 11.3.3.4. Market Developments
    • 11.3.3.5. Market Strategy
  • 11.3.4. Vanita Therapeutics
    • 11.3.4.1. Overview
    • 11.3.4.2. Segments and Product
    • 11.3.4.3. Key Financials
    • 11.3.4.4. Market Developments
    • 11.3.4.5. Market Strategy
  • 11.3.5. Alvogen
    • 11.3.5.1. Overview
    • 11.3.5.2. Segments and Product
    • 11.3.5.3. Key Financials
    • 11.3.5.4. Market Developments
    • 11.3.5.5. Market Strategy
  • 11.3.6. Pfizer, Inc.
    • 11.3.6.1. Overview
    • 11.3.6.2. Segments and Product
    • 11.3.6.3. Key Financials
    • 11.3.6.4. Market Developments
    • 11.3.6.5. Market Strategy
  • 11.3.7. Nua
    • 11.3.7.1. Overview
    • 11.3.7.2. Segments and Product
    • 11.3.7.3. Key Financials
    • 11.3.7.4. Market Developments
    • 11.3.7.5. Market Strategy
  • 11.3.8. Cora
    • 11.3.8.1. Overview
    • 11.3.8.2. Segments and Product
    • 11.3.8.3. Key Financials
    • 11.3.8.4. Market Developments
    • 11.3.8.5. Market Strategy
  • 11.3.9. Roche Laboratories
    • 11.3.9.1. Overview
    • 11.3.9.2. Segments and Product
    • 11.3.9.3. Key Financials
    • 11.3.9.4. Market Developments
    • 11.3.9.5. Market Strategy
  • 11.3.10. Taj Pharmaceuticals, Ltd.
    • 11.3.10.1. Overview
    • 11.3.10.2. Segments and Product
    • 11.3.10.3. Key Financials
    • 11.3.10.4. Market Developments
    • 11.3.10.5. Market Strategy
  • 11.3.11. Sanofi
    • 11.3.11.1. Overview
    • 11.3.11.2. Segments and Product
    • 11.3.11.3. Key Financials
    • 11.3.11.4. Market Developments
    • 11.3.11.5. Market Strategy
  • 11.3.12. Terramedic, Inc.
    • 11.3.12.1. Overview
    • 11.3.12.2. Segments and Product
    • 11.3.12.3. Key Financials
    • 11.3.12.4. Market Developments
    • 11.3.12.5. Market Strategy

12. Appendix

• 12.1. Research Methodology
• 12.2. Research Assumptions
• 12.3. Acronyms and Abbreviations